Artivion (AORT)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$25.33-4.23%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · AORT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 20.8% |
| Our one-year growth estimate | diamond | 13.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers · Company calendar date is not available
AORT — earnings miss
Dated 2026-11-05
of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of Artivion’s reports or filings with the Securities and Exchange Commission (the “SEC”), whether made before or after the date hereof, except as expressly set forth by specific refer…
Why it matters: Artivion plans to launch NEXUS in the U.S. after building stock and getting hospital approvals. Early sales will test demand for the acquired product.
Supportive ifArtivion reports U.S. NEXUS sales after Jan. 1, 2027, and names hospitals or sales progress.
Worry ifThe launch slips past Jan. 1, 2027, or Artivion reports no U.S. sales after launch.
Why it matters: These products drove Q2 growth. A slowdown could weaken Artivion's sales pace; continued gains would back its current growth story.
Watch forQ3 constant-currency growth stays positive for both On-X and stent grafts.
Also watch forEither On-X or stent graft revenue falls year over year on a constant-currency basis in Q3.
Why it matters: Q2 adjusted EBITDA grew 7%, while the full-year target is $92M–$99M. The next report will show whether earnings growth is keeping pace.
Worry ifQ3 adjusted EBITDA and updated results put the $92M–$99M full-year target out of reach.
Less concerning ifQ3 results support the $92M–$99M target, with full-year guidance kept or raised.
Why it matters: Artivion cut its revenue range in Q1, then kept it in Q2. The Nov. 5 report will test whether growth stays on track.
Worry ifOn Nov. 5, Artivion lowers its 2026 revenue range below $480M, or reports results that put the range at risk.
Less concerning ifArtivion keeps its $480M–$496M range and reports revenue growth within its 7%–11% full-year goal.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $441 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,780 loss on $10,000 · 57.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.